02210nas a2200409   4500000000100000008004100001260001300042653001500055653001000070653001600080653001200096653003000108653001100138653001100149653002300160653001200183653000900195653001600204653001600220653001400236653001300250100001900263700001500282700001300297700001500310700001500325700001100340700001000351700001300361700001300374245017800387300001200565490000700577050002200584520118000606022001401786       2004                            d  c2004 Feb10aAdolescent10aAdult10aClofazimine10aDapsone10aDrug Therapy, Combination10aFemale10aHumans10aLeprostatic Agents10aleprosy10aMale10aMiddle Aged10aMinocycline10aOfloxacin10aRifampin1 aVillahermosa L1 aFajardo TT1 aAbalos R1 aCellona RV1 aBalagon MV1 aCruz E1 aTan E1 aWalsh GP1 aWalsh DS00aParallel assessment of 24 monthly doses of rifampin, ofloxacin, and minocycline versus two years of World Health Organization multi-drug therapy for multi-bacillary leprosy.  a197-2000 v70  aVILLAHERMOSA 20043 a<p>Monthly doses of rifampin, ofloxacin, and minocycline (ROM) are expected to be effective treatment for multi-bacillary leprosy. Patients with MB leprosy received ROM (n = 10) or World Health Organization multi-drug therapy (MDT) (n = 11). Treatment with ROM was given as 24 consecutive monthly observed doses of rifampin (600 mg), ofloxacin (400 mg), and minocycline (100 mg). Treatment with MDT was given as 24 consecutive monthly observed doses of rifampin (600 mg) and clofazimine (300 mg), and unobserved daily dapsone (100 mg) and clofazimine (50 mg). Twenty patients completed the 24-month regimens with > 99% compliance. Treatments with ROM and MDT were safe, tolerable, and caused similar improvements in lesions, bacterial indices, and histology. All MDT recipients developed clofazimine-induced pigmentation. Six ROM and nine MDT recipients assessed at five or more years after completion of treatment had no evidence of relapse. Twenty-four months of treatment with ROM is a safe, well-tolerated, and convenient regimen that may provide an alternate therapy to MDT for MB leprosy. Larger trials with sufficient follow-up would better define the role of ROM.</p>  a0002-9637